In Conversation with John Swartley, Chief Innovation Officer, University of Pennsylvania BioBuzz CEO Chris Frew interviews John Swartley, Penn’s Chief Innovation Officer, discussing his role in advancing university-led innovation, corporate [….]
Regenxbio and UPenn Lose Legal Battle Over Muscular Dystrophy Treatment Patent to Sarepta Published on January 6, 2024 In a major legal showdown over patents and innovation, Sarepta Therapeutics (SRPT.O) [….]
Weekly Quick Hits (Greater Philly) – Week of May 29, 2023 By Mark TerryJune 2, 2023 Funding, Awards and Collaborations CHOP and More than 20 Institutions Create Open-Analysis Platform for [….]
Weekly Quick Hits (Greater Philly) – Week of May 8, 2023 By Mark TerryMay 12, 2023 Funding, Awards and Collaborations Interius Announces Manufacturing Partnership with WuXi Advanced Therapies Philadelphia-based Interius [….]
Weekly Quick Hits (Greater Philly) – Week of April 17, 2023 By Mark Terry, Alex Keown, and Sarah EllinwoodApril 21, 2023 Funding, Awards and Collaborations TELA Bio Announces Pricing of [….]
Penn and Michael J. Fox Foundation ID Breakthrough Biomarker in Parkinson’s Disease By Mark TerryApril 17, 2023 Researchers with the University of Pennsylvania Perelman School of Medicine and others, with [….]
Here’s what’s been happening Greater Philadelphia’s Life Science scene the week of January 23, 2023
Sponsored by the not-for-profit Uplifting Athletes, the Young Investigators Draft provides $20,000 grants to 10 beginning-career stage research scientists in the rare disease community. The award is an unrestricted grant that will support the vital investigation of potential therapies and cures, including gene therapies, for rare disease, said Rob Long, executive director of Uplifting Athletes.
In a wide-ranging discussion, the panel discussed how they got into working with mRNA, what they’ve seen as key drivers in the field (COVID-19, of course, was major), and what they’re excited to see in the future.
Cellicon Valley companies closed out 2022 with a roar. Madrigal Pharmaceuticals announced a breakthrough in NASH that could result in the first-approved drug for that disease. Galera Therapeutics closed out December with plans to seek approval for its severe oral mucositis therapy.
